We have entered into a variety of contractual arrangements to use our XenoMouse and XenoMax technologies to generate and/or develop fully human antibodies against numerous antigens or to manufacture fully human antibodies. The following is a summary of these relationships.
Company profile
Ticker
ABGX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
943248826
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
27 Jul 15
CT ORDER
Confidential treatment order
18 May 12
CT ORDER
Confidential treatment order
3 Nov 09
CT ORDER
Confidential treatment order
22 Oct 09
15-12G
Securities registration termination
3 Apr 06
POS AM
Prospectus update (post-effective amendment)
3 Apr 06
POS AM
Prospectus update (post-effective amendment)
3 Apr 06
POS AM
Prospectus update (post-effective amendment)
3 Apr 06
POS AM
Prospectus update (post-effective amendment)
3 Apr 06
POS AM
Prospectus update (post-effective amendment)
3 Apr 06
Latest ownership filings
No filings